• Zealand Pharma entered a collaboration and license agreement with Generate Biomedicines to develop AI-engineered multispecific protein therapeutics for obesity, other metabolic diseases.
• Generate to receive USD 30 million upfront, up to USD 35 million in early preclinical milestones for two initial programs.
• Total potential milestones set at nearly USD 1.2 billion, with tiered royalties; Zealand holds an option to add a third program.
• Deal broadens Zealand’s capabilities beyond peptides into protein therapeutics, extending Generate’s platform into obesity and metabolic indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610131630PRIMZONEFULLFEED1001277765) on October 13, 2026, and is solely responsible for the information contained therein.